These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 30872517)

  • 21. Opportunities and Challenges in Drug Development for Pediatric Cancers.
    Laetsch TW; DuBois SG; Bender JG; Macy ME; Moreno L
    Cancer Discov; 2021 Mar; 11(3):545-559. PubMed ID: 33277309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
    Beer PA; Cooke SL; Chang DK; Biankin AV
    Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
    [No Abstract]   [Full Text] [Related]  

  • 24. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.
    Kato S; Subbiah V; Kurzrock R
    J Natl Compr Canc Netw; 2017 Jul; 15(7):863-866. PubMed ID: 28687573
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalised medicine in paediatric oncology: Ethical practice outside the clinical trial framework?
    Hansford JR
    J Paediatr Child Health; 2019 Jan; 55(1):10-12. PubMed ID: 30499210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 29. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomics and the History of Precision Oncology.
    Doroshow DB; Doroshow JH
    Surg Oncol Clin N Am; 2020 Jan; 29(1):35-49. PubMed ID: 31757312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspective on Precision Medicine in Oncology.
    Johnson TM
    Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials.
    Doostparast Torshizi A; Wang K
    Drug Discov Today; 2018 Oct; 23(10):1776-1783. PubMed ID: 29758342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hubris and humility of cancer pharmacology in the post immuno-oncology era.
    Lazo JS
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00527. PubMed ID: 31624635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steps forward for cancer precision medicine.
    Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D;
    Nat Rev Drug Discov; 2018 Jan; 17(1):1-2. PubMed ID: 29170471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community-driven development of a modified progression-free survival ratio for precision oncology.
    Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
    ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.